Context Therapeutics (NASDAQ:CNTX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, reports.
Context Therapeutics Trading Up 3.3 %
CNTX traded up $0.03 during midday trading on Friday, hitting $0.80. The company’s stock had a trading volume of 15,405 shares, compared to its average volume of 387,480. Context Therapeutics has a 52-week low of $0.64 and a 52-week high of $2.75. The firm has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $1.45. The firm has a market cap of $59.70 million, a P/E ratio of -0.87 and a beta of 2.06.
Analyst Ratings Changes
Several research firms have issued reports on CNTX. JMP Securities started coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $6.17.
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- 5 discounted opportunities for dividend growth investors
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
